Young COVID-19 Stroke Victims; Alzheimer’s Seaweed Drug; Parkinson’s Med OK’d
COVID-19 linked to large vessel stroke in young adults, which showed either mild or no symptoms of infection. However, according to a Mount Sinai Hospital neuro-interventionalist and others. (CNN)
FDA filings for aducanumab, Biogen’s controversial Alzheimer’s drug candidate, will delayed until the third quarter, the company announced.
Shanghai Green Valley Pharmaceutical received FDA clearance for the U.S. part of a global trial of its seaweed-based Alzheimer’s drug oligomannate, which received conditional approval in China last year. (Bloomberg)
Pediatric patients with anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis also showed brain volume loss and reduced age-expected brain growth in a longitudinal study. (Annals of Neurology)
Cognitive decline in Parkinson’s disease differed from decline in dementia with Lewy bodies in a cognitive domain-specific manner. (Neurology)
Is white matter degeneration a treatable target? (JAMA Neurology)
Duloxetine (Cymbalta) did not improve pain in Parkinson’s disease over 10 weeks, but exploratory analyses suggested it may ease motor symptoms and improve quality of life. (Journal of the Neurological Sciences)
And spinal cord stimulation in very severe Parkinson’s did not lead to significant mobility improvements, a 1-year trial showed. (Movement Disorders)
Oral opicapone (Ongentys), an add-on treatment to levodopa/carbidopa in Parkinson’s patients experiencing “off” episodes, won FDA approval and will be launched later this year, Neurocrine announced.
Experts published consensus recommendations about epilepsy care during COVID-19. (Neurology)